DocumentsDate added
Original article
Lisha Jenny John1*, M.D., Jayakumary Muttappallymyalil2, M.D., Elsheba Mathew2, M.D, M.Phil, Jayadevan Sreedharan3,PhD, Jenny John Cheriathu4,D.N.B.,
Masarat Mehboob5,M.D. & Annamma Mathew6, BPT
Affiliation:
1Department of Pharmacology, 2Department of Community Medicine, 3Statistical Support Facility, CABRI, Gulf Medical University, Ajman, UAE
4Department of Pediatrics, 5Department of Internal Medicine, Department of Allied Health Science, Gulf Medical College Hospital, Ajman, UAE.
Author’s contributions:
Lisha Jenny John contributed in study design, literature search, manuscript writing and editing.
Jayakumary Muttappallymyalil contributed in study design, manuscript editing, and review
Elsheba Mathew contributed towards concept and study design, manuscript review.
Jayadevan Sreedharan contributed in data management and statistical analysis, manuscript review.
Jenny John Cheriathu, Masarat Mehboob & Annamma Mathew contributed in data acquisition.
*Correspondence to:
Dr. Lisha Jenny John.
Department of Pharmacology, Gulf Medical University, Ajman, UAE
Ph: +97167431333
Fax No: +97167431222
Core tip:
With the widespread use of Complementary and alternative medicine for various illnesses, it has been increasingly accepted and integrated into conventional medicine by health care providers. This study explored the acceptability and utilization of CAM therapies among health care providers.
Abstract:
Acceptability, utilization pattern and reasons for opting CAM among health care providers in a tertiary care centre in Ajman, UAE was assessed in the study. A sample of thirty six health care providers filled in the self-administered questionnaire after giving consent. The questionnaire included socio-demographic characteristics, practice and attitude towards CAM, and reasons for self use. Descriptive statistics and Chi-square test were performed using PASW 18 version and p value <0.05 considered statistically significant.
The respondents were multinationals, age ranging from 26-70 years, 39% of the health care providers themselves used CAM, joint pain was the most common clinical condition, common forms of CAM practiced were Ayurveda and homeopathy (35.7% each), and the outcome of CAM use was good for majority of the health care providers. Family history of CAM use was noted in 78.6% respondents. Based on personal experience with CAM, 30.6% recommended CAM to others. The chief reason for self-use and recommending CAM is its fewer side effects. Around 69% did not use or recommend CAM, and the reason quoted was CAM is not scientific. The primary reason for practice and recommendation of CAM is fewer adverse effects while the lack of scientific evidence is the reason for others not to favor CAM.
Key Words: Acceptability; practice; complementary medicine, health care providers; UAE.
References
1.World Health Organization: Fact Sheet No. 134: Traditional medicine. [http://www.who.int/mediacentre/factsheets/fs134/en/index.html].
2.Richardson MA, Masse LC, Nanny K, et al. Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Support Care Cancer 2004;12:797-804.[Pubmed]
3.Hyodo I, Eguchi K, Nishina T, et al. Perceptions and attitudes of clinical oncologists on complementary and alternative medicine. Cancer 2003;97:2861-2868. [Pubmed]
4.Risberg T, Kolstad A, Bremnes Y, et al. Knowledge of and attitudes toward complementary and alternative therapies: a national multicentre study of oncology professionals in Norway. Eur J Cancer 2004;40:529-535. [Pubmed]
5.Boutin PD, Buchwald D, Robinson L, et al. Use of and attitudes about alternative and complementary therapies among Outpatients and physicians at a municipal hospital. J Altern Complement Med 2000;6:335-343.[Pubmed]
6.Schmidt K, Jacobs PA, Barton A,et al. Cross-cultural differences in GPs' attitudes towards complementary and alternative medicine: a survey comparing regions of the UK and Germany. Complement Ther Med 2002;10(3):141-147.[Pubmed]
7.Kaczorowski J, Patterson C, Arthur H, et al. Complementary therapy involvement of physicians: implications for practice and learning. Complement Ther Med 2002;10(3):134-140. [Pubmed]
8.Kurtz ME, Nolan RB, Rittinger WJ. Primary care physicians' attitudes and practices regarding complementary and Alternative medicine. J Am Osteopath Assoc 2003;103(12):597-602.[Pubmed]
9.M. J. Leach. Public, nurse and medical practitioner attitude and practice of natural Medicine. Complement Ther Nurs Midwifery 2004;10:13-21. [Pubmed]
10.Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. N Engl J Med 1993;328:246-252.[Pubmed]
11.Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA 1998;280:1569-1575. [Pubmed]
12.Richardson MA, Sanders T, Palmer JL, et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000;18:2505-2514. [Pubmed]
13.Hyodo I, Amano N, Eguchi K, et al. Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 2005;23:2645-2654. [Pubmed]
14.Lee SI, Khang YH, Lee MS, et al. Knowledge of attitudes toward, and experience of complementary and alternative medicine in Western medicine- and oriental medicine- trained physicians in Korea. Am J Public Health 2002;92:1994-2000.[Pubmed]
15.Giannelli M, Cuttini M, Da Frè M, et al. General practitioners' knowledge and practice of complementary/alternative medicine and its relationship with life-styles: a population-based survey in Italy. BMC Fam Pract 2007;8:30.[Pubmed]
16.Pirotta M, Farish SJ, Kotsirilos V, et al. Characteristics of Victorian general practitioners who practice complementary therapies. Aust Fam Physician 2002;31:1133-1138.[Pubmed]
17.Schachter L, Weingarten M, Kahan E. Attitudes of family physicians to nonconventional therapies. A challenge to science as the basis of therapeutics. Arch Fam Med 1993;2:1268-1270.[Pubmed]
18.Thomas K, Nicholl J, Fall M. Access to complementary medicine via general practice. Br J Gen Pract 2001;51:25-30. [Pubmed]
19.Verhoef M, Sutherland L. Alternative medicine and general practitioners. Opinions and behaviour. Can Fam Physician 1995;41:1005-1011.[Pubmed]
20.Marshall R, Gee R, Israel M, et al. The use of alternative therapies by Auckland general practitioners. N Z Med J 1990;103:213-215.[Pubmed]
21.Hall K, Giles-Corti B. Complementary therapies and the general practitioner. A survey of Perth GPs. Aust Fam Physician 2000;29:602-606.[Pubmed]
22.Visser G, Peters L. Alternative medicine and general practitioners in The Netherlands: towards acceptance and integration. Fam Pract 1990; 7:227-232. doi: 10.1093/fampra/7.3.227.[Pubmed]
23.Himmel W, Schulte M, Kochen M. Complementary medicine: are patients' expectations being met by their general practitioners? Br J Gen Pract 1993;43:232-235. [Pubmed]
24.Fujiwara K, Imanishi J, Watanabe S, et al. Changes in Attitudes of Japanese Doctors toward Complementary and Alternative Medicine—Comparison of Surveys in 1999 and 2005 in Kyoto.Evid Based Complement Alternat Med 2011;2011:608921. Available at doi:10.1093/ecam/nep040 (Accessed on 20th June 2011).[Pubmed]
25.Gogtay NJ, Bhatt HA, Dalvi SS, et al. The use and safety of non-allopathic Indian medicines. Drug Saf 2002;25:1005-19.[Pubmed]
26.Botting A, Cook R. Complementary medicine: knowledge, use and attitudes of doctors. Complement Ther Med 2000;6:41-47. [Pubmed]
27.Milden SP, Stokols D. Physicians' attitudes and practices regarding complementary and alternative medicine. Behav Med 2004;30(2):73-82.[Pubmed]
Article citation:-
Lisha Jenny John,Jayakumary Muttappallymyalil, Elsheba Mathew,Jayadevan Sreedharan,Jenny John Cheriathu, Masarat Mehboob et al. Acceptability and utilization of complementary medicine among health care providers: A pilot study. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35): 1727-1731.
Copyright © 2013 Lisha Jenny John, Jayakumary Muttappallymyalil, Elsheba Mathew, Jayadevan Sreedharan, Jenny John Cheriathu, Masarat Mehboob et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review:
Peyman Mikaili1, Maziar Koohirostamkolaei2, Seyed Sajjad Babaeimarzangou2, Shahin Aghajanshakeri2*, Milad Moloudizargari2, Naeimeh Shamsi Gamchi2, Sepideh Toloomoghaddam3
Affiliation:-
1Department of Pharmacology, Faculty of Pharmacy, Urmia University of Medical Sciences, Urmia, Iran
2Faculty of Veterinary Medicine, Urmia University, Urmia, Iran
3Faculty of Pharmacy, Islamic Azad University of Pharmaceutical Sciences, Tehran, Iran
*Correspondence to:-
Shahin Aghajanshakeri.
Faculty of Veterinary Medicine, Urmia University, Urmia, Iran
Email id: Shahin.aghajanshakeri@yahoo.com
Abstract:
Cornelian cherry fruit has been used in Chinese herbal medicine and is known for its tonic, analgesic and diuretic activities. Its extracts are also used in Europe for cosmetic determinations, replacing synthetic astringent substances, and are claimed to exert a favourable action on the human complexion. Cornus officinalis, C. mas, C. kousa (Cornaceae), and C. controversa bear edible fruits that are consumed in some parts of Asia and Europe. The anthocyanins (ANTs) present in Cornelian cherry, C. mas, are cyaniding 3-O-beta-galactopyranoside, delphinidin 3-O-beta-galactopyranoside, and pelargonidin 3-O-beta-galactopyranoside. C. mas is a medical plant from Cornaceae family which contains flavonoids and is high in antioxidants with anti-inflammatory activities. Fresh cornelian cherry (Cornus mas L.) fruits encompass twice as much ascorbic acid (vitamin C) as oranges.
Key words: Pharmacological effects; Cornus mas; Anthocyanins; Ursolic acid.
References:
1. Celik S, Bakirci I, S¸at IG. Physicochemical and organoleptic properties of yogurt with cornelian cherry paste. Int J Food Property 2006; 9:401–408.
2. Hassanpour H, Hamidoghli Y, Hajilo JB, Adlipour M. Antioxidant capacity and phytochemical properties of cornelian cherry (Cornus mas L.) genotypes in Iran. Scientia Horticulturae 2011; 129: 459–463.[Sciencedirect][Google scholar]
3. Du CT, Francis FJ.Anthocyanins from Cornus mas. Phytochemistry 1973a; 12, 2487–2489.[Scopus]
4. Du C T, Francis F J. New anthocyanin from Cornus mas.HortScience 1973b; 8, 29–30.
5. Seeram NP, Schutzki R, Chandra A, Nair MG. 2002. Characterization, quantification, and bioactivities of anthocyanins in Cornus species. J Agric Food Chem. 24;50(9): 2519-23.[Pubmed]
6. Tural S, Koca I. Physico-chemical and antioxidant properties of cornelian cherry fruits (Cornus mas L.) grown in Turkey. Scientia Horticulturae 2008; 116: 362–366.[Scopus][Google scholar]
7. Jayaprakasam B, Olson LK, Schutzki RE, Tai MH, Nair MG. Amelioration of obesity and glucose intolerance in high-fat-fed C57BL/6 mice by anthocyanins and ursolic acid in Cornelian cherry (Cornus mas). J Agric Food Chem 2006; 54(1): 243-8.[Pubmed]
8. Asgary S, Adelnia A, Kazemi S, Rafieian-Kopaei M, Shamsi M. Effect of cornus mas L. on atherosclerotic plaque in hypercholesterolemic rabbits. Atherosclerosis 2010;Supplements 11 (2): 109–222.
9. Rimm EB, Aschiero A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetables, fruit, and cereal fiber intake and risk of coronary heart disease among men. J Am Med Assoc 1996; 275: 447–451.[Pubmed]
10. Terry P, Terry JB, Wolk A. 2001. Fruit and vegetable consumption in the prevention of cancer. an update J Intern Med 2001; 250: 280–290.[Pubmed]
11. Ziegler RG. Vegetables, fruits and carotenoids and the risk of cancer. Am J Clin Nutr1991; 53: 251–259.[Pubmed]
12. Kähkönen MP, Heinonen M. Antioxidant activity of anthocyanins and their aglycons. Journal of Agricultural and Food Chemistry 2003; 51, 628–633.[Pubmed]
13. Xu JW, Ikeda K, Yamori Y. Upregulation of endothelial nitric oxide synthase by cyanidin-3-glucoside, a typical anthocyanin pigment. Hypertension 2004;44: 217–222.[Pubmed]
14. Seeram N. Berry fruits: Compositional elements, biochemical activities, and the impact of their intake on human health, performance, and disease. Journal of Agricultural and Food Chemistry 2008; 56:627–629.[Pubmed]
15. Tsuda T, Horio F, Uchida K, Aoki H, Osawa T. Dietary cyanidin 3-O-beta- D-glucoside-rich purple corn color prevents obesity and ameliorates hyperglycemia in mice. The Journal of Nutrition 2003;133: 2125–2130.[Pubmed]
16. Takikawa M, Inoue S, Horio F, Tsuda T. Dietary anthocyanin-rich bilberry extract ameliorates hyperglycemia and insulin sensitivity via activation of AMPactivated protein kinase in diabetic mice. The Journal of Nutrition 2010;140: 527–533.[Pubmed]
17. Pieroni A. Local plant resources in the ethnobotany of theth,a village in the northern Albanian alps. Genet Resour Crop Evol 2008;55: 1197–1214.[Original source]
18. Renata A, Sancho S, Pastore MG. Evaluation of the effects of anthocyanins in type 2 diabetes . Food Research International 2012;46: 378–386.[Scopus]
19. Jung SH, Ha YJ, Shim EK, et al. Insulin-mimetic and insulinsensitizing activities of a pentacyclic triterpenoid insulin receptor activator. Biochem 2007;J 403: 243-50.[Pubmed]
20. Jang MS, Kimb JM, Choic SM, Kwonc YE, Lee KM. Inhibitory effects of ursolic acid on hepatic polyol pathway and glucose production in streptozotocin-induced diabetic mice. Metabolism Clinical and Experimental 2010;59: 512–519. doi: 10.1016/j.metabol.2009.07.040. Epub 2009 Oct 28.[Pubmed]
21. Asgary S, Rafieian-Kopaei M, Adelnia A, Kazemi S, Shamsi M. Comparing the effect of lovastatin and cornus mas fruit on fibrinogen level in hypercholesterolemic rabbits. Arya Atheroscler 2010;6 (1): 1-5.[Pubmed]
22. Liu Y, Tian W, Ma X, Ding W. Evaluation of inhibition of fatty acid synthase by ursolic acid: Positive cooperation mechanism.Biochemical and Biophysical Research Communications 2010; 392: 386–390.[Pubmed]
23. Saraswat B, Visen PKS, Dayal R, et al. Protective action of ursolic aci against chemical induced hepatotoxicity in rats. Indian J Pharmacol 1996;28: 232-9.
24. Rodriguez JA, Astudillo L, Schmeda-Hirschmann G. 2003. Oleanolic acid promotes healing of acetic acid-induced chronic gastric lesions in rats. Pharmacol Res 48: 291-4.[Pubmed]
25. Saladin R, De Vos P, Guerre-Millo M, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995;377: 527-9.[Pubmed]
26. Vareed SK, Reddy MK, Schutzki RE, Nair MG. Anthocyanins in Cornus alternifolia, Cornus controversa, Cornus kousa and Cornus florida fruits with health benefits. 2006;Life Sci 78: 777–784.[Pubmed]
27. Raphael TJ, Kuttan G. Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune system. Phytomedicine 2003; 10: 483-9.
[Pubmed]
28. Banno N, Akihisa T, Tokuda H, et al. Triterpene acids from the leaves of Perilla frutescens and their anti-inflammatory and antitumorpromoting effects. Biosci Biotechnol Biochem 2004;68: 85-90.[Pubmed]
29. Krośniak M, Gastoł M, Szałkowski M, Zagrodzki P, Derwisz M. Cornelian cherry (cornus mas L.) juices as a source of minerals in human diet. J Toxicol Environ Health A 2010;73 (17-18): 1155-8.[Pubmed]
30. Lee I, Lee J, Lee YH, et al. Ursolic acid-induced changes in tumor growth, O2 consumption, and tumor interstitial fluid pressure. Anticancer Res 2110;21: 2827-34.[Pubmed]
31. Leskovac A, Joksic G, Jankovic T, Savikin K, Menkovic N. Radioprotective properties of the phytochemically characterized extracts of Crataegus monogyna, Cornus mas and Gentianella austriaca on human lymphocytes in vitro. Planta Med 2007;73(11): 1169-75.[Pubmed]
32. Savikin K, Zdunic G, Jankovic T, Stanojkovic T, Juranic Z, Menkovic N. In vitro cytotoxic and antioxidative activity of Cornus mas and Cotinus coggygria. Nat Prod Res 2009; 23 (18): 1731-1739.[Pubmed]
33. Lapidot T, Walker MD, Kanner J. Antioxidant and prooxidant effects of phenolics on pancreatic beta-cells in vitro. Journal of Agricultural and Food Chemistry 2002; 50:7220–7225.[Pubmed]
34. Valentova K, Moncion A, deWaziers I, Ulrichova J. The effect of Smallanthus sonchifolius leaf extracts on rat hepatic metabolism. Cell Biology and Toxicology 2004;20, 109–120.[Pubmed]
35. Jayaprakasam B, Vareed SK, Olson LK, Nair MG. Insulin secretion by bioactive anthocyanins and anthocyanidins present in fruits. J. Agric. Food Chem 2005; 53, 28–31.[Pubmed]
36. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995;49: 57-68.[Pubmed]
37. Lee HY, Chung HY, Kim KH, et al. Induction of differentiation in the cultured F9 teratocarcinoma stem cells by triterpene acids. J CancerRes Clin Oncol 1994;120: 513-8.[Pubmed]
38. Somova LO, Nadar A, Rammanan P, et al. Cardiovascular, antihyperlipidemic and antioxidant effects of oleanolic and ursolic acids in experimental hypertension. Phytomedicine 2003; 10: 115-21.[Pubmed]
39. Asgary S, Shamsi F, Kazemi S, Adelneia A, Rafieian M. Pretreatment effect of Cornus mas L. on alloxan induced diabetes in rats. Atherosclerosis 2010; Supplements 11(2): 109–222.
Article citation:-
Peyman Mikaili, Maziar Koohirostamkolaei, Seyed Sajjad Babaeimarzangou, Shahin Aghajanshakeri, Milad Moloudizargari, Naeimeh Shamsi Gamchi, et al. Therapeutic uses and pharmacological effects of Cornus mas: A review. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35): 1732-1738. Available at http: //www.jpbms.info
Copyright © 2013 Peyman Mikaili, Maziar Koohirostamkolaei, Seyed Sajjad Babaeimarzangou, Shahin Aghajanshakeri, Milad Moloudizargari, Naeimeh Shamsi Gamchi, et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Review article
* Sam Straw
Affiliation:-
*Medical student, Scleroderma Research Group, Leeds Institute of Molecular Medicine, St James’ University Hospital, Beckett Street, Leeds, LS9 7TF, UK.
*Corresponding author:
Sam Straw.
Medical student, Scleroderma Research Group, Leeds Institute of Molecular Medicine, St James’ University Hospital, Beckett Street, Leeds, LS9 7TF, UK
Abstract:
Systemic sclerosis (SSc) is a highly heterogeneous disease which would benefit from the adoption of a stratified medicine approach, to improve outcomes for patients and reduce costs to the healthcare system. SSc is orphan of disease activity biomarkers, as the current gold standard prognostic test: the modified Rodnan skin score (MRSS) is flawed. The MRSS has been shown to be unreliable, insensitive to change and not specific in measuring skin fibrosis. Physical measurements of skin thickness, genetic risk factors and autoantibodies may all allow patient stratification, however as proteins are the mediators of biological function; proteomics may offer the best approach. Proteomic studies to identify biomarkers are hypothesized to fulfill the outcome measured in rheumatology (OMERACT) filter criteria of: truth, discrimination and feasibility.
Key words: Stratified medicine; scleroderma; systemic sclerosis; biomarkers; health economics; modified Rodnan skin score; OMERACT; proteomics; autoantibodies; genetic risk factor; skin thickness.
References:
1.Castro S, J.S., Biomarkers in systemic sclerosis. Biomarkers Med 2010;4(1): 133-147.
2. Moon, Ki Won; Song, Ran; Kim, Jin Hyun; Lee, Eun Young; Lee, Eun Bong; Song, Yeong Wook. Rheumatology International
2012 August ;32(8); 2465 – 2470. DOI: 10.1007/s00296-011-1993-9.
3.Matucci-Cerinic M, S.V., Nash P, et al., The complexity of managing systemic sclerosis: screening and diagnosis. Rheumatology 2009; 48: iii8-iii13.
4.Furst D, K.D., Matucci-Cerinic M, et al., Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 2007; 34:1194-1200.
5.Czirják L, N.Z., Aringer M, et al., The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosis. Ann Rheum Dis 2007; 66(7):966-969.
6.Chifflot H, F.B., Sordet C, et al., Incidence and Prevalenc of Systemic Sclerosis: A Systemic Literature Review. Semin. Arthritis Rheum 2007; 37(4): 223-235.
7.Abignano G, B.M., Emery P, Del Galdo F, Biomarkers in the management of scleroderma: An update. Curr Rheumatol Rep 2011; 13(4): 4-12.
8.Kaldas M, K.P., Furst D, et al., Sensitivity to change of the moodified Rodnan skin score in diffuse systemic sclerosis - assessment of individual body sites in two large randomized clinical trials. Rheumatology 2009; 48(9):1143-1146.
9.Clements P, L.P.S.J., et al., Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993 20(11):1892-1896.
10.Czirják L, F.I., Müller-Ladner U, Skin involvement in systemic sclerosis. Rhuematology (Oxford) 2008; 47(5):44-45.
11.Moinzadeh P, D.C., Ong V, et al., Biomarkers for skin involvement and fibrotic activity in scleroderma. JEADV.
12.Trusheim M, B.E., Douglas F, Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews: Drug Discovery 2007; 6:287-293.
13.B, H., Developing tools for stratified medicine. Nat Rev Drug Discov, 2009; 8(12):919-920.
14.NICE recommends trastuzumab (Herceptin) for advanced breast cancer. 2010 28/12/2010 25/11/2011]; Available from: http://www.nice.org.uk/guidance/index.jsp?action=article&r=true&o=32318.
15.J, R., Letter from the Editor: stratified medicine. MAbs 2010; 2(2): 107.
16.Chasman J, P.D., Subrahmanyan L, et al., Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 2004; 291(23): 2821-2827.
17.Bernatsky S, H.M., Panopalis P, et al., The cost of systemic sclerosis. Arthritis and Rheumatism 2009; 61(1):119-123.
18.Boers M, B.P., Strand CV, et al., The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25(2):198-199.
19.Del Galdo F, S.A., Jimenez S, Proteomic analysis identification of a pattern on shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis. Am J Pathol 2010; 177(4):1638-1645.
20.Ionescu R, R.S., Damjanov N, et al., Repeated teeaching courses of the modified Rodnan skin score in systemic sclerosis. Clin Exp Rheumatol 2010; 28(2):37-41.
21.Furst D, C.P., Steen V, et al., The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25(1): 84-88.
22.Postlewaite A, W.W., Clements P, et al., A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis. I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 2008; 58:1810-1822.
23.Khanna D, C.P., Furst D, et al., Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2009; 60:1102-1111.
24.Rohekar G, P.J., Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. J Rheumatol 2009; 36(10):2178-2182.
25.Milano A, P.S., Sargent J, et al., Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008; 3(10):e2696.
26.Kissin E, S.A., Gelbard R, et al., Durometry for the assessment of skin disease and systemic sclerosis. Arthritis Rheum 2006; 55(4):603-609.
27.Domsic R, R.-R.T., Lucas M, et al., Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 2011; 70:104-109.
28.Arnett G, G.P., Shete S, et al., Major histocompatability complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis 2010; 69:822-827.
29.Gorman C, R.A., Zhang Z, et al., Polymorphisms in the CD3Z gene influence TCRzeta expression in systemic lupus erythematous patients and healthy controls. J Immunol 2008; 180:1060-1070.
30.Glas J, S.J., Nagy M, et al., Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS ONE, 2010. 5(e10373).
31.Morgan A, R.J., Conahan P, et al., Evaluation of the rheumatoid arthritis susceptability loci HLA-DRB1, PTPN22, OLIG3/TNFAIP£, STAT4 and TRAF1/C5 in an inception cohort. Arthritis Res Ther 2010; 12(R57).
32.Gorlova O, M.J., Reuda B, et al., Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genet 2011; 7(7): e1002178.
33.V, S., Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum 2005; 35:35-42.
34.Shero J, B.B., Rothfield N., High titers of autoantibodies to topoisomerase I (scl-70) in sera from scleroderma patients. Science 1986; 231:737-740.
35.Czömpöly T, S.D., Czirják L, Antitopoisomerase I autoantibodies in systemic sclerosis. Autoimmun. Rev2009; 8: 692-696.
36.CG., K., Anti-centromere antibodies (ACA). Clin. Rheumatol 1990; 9:S136-S139.
37.Basu D, R.J., Anti-Scl-70. Autoimmunity 2005 38:65-72.
38.LeRoy E, B.C., Fleischmajer R et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202-205.
39.Tramposch H, S.C., Senecal J, et al., A long-term longitudinal study of anticentromere antibodies. Arthritis Rheum 1984; 27:121-124.
40.Bargagli E, O.C., Prasse A, et al., Calgranulin B (S100A9) levels in bronchoalveolar lavage fluid of patients with intersitital lung diseases. Inflammation, 2008 31:351-354.
41.Rottoli P, M.B., Perari M, et al., Cytokine profile and proteome analysis in bronchoalveolar lavage fluid of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. Proteomics 2005 5:1423-1430.
42.Giusti L, B.L., Baldini C et al., Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol 2007; 34: 2063-2069.
43.Bogatkevich G, L.-B.A., Singleton C, et al., Proteomic analysis of CTGT-activated lung fibroblats: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol 2008. 295:L603-L611.
44.Aden N, S.X., Aden D, et al., Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology 2008 47: 1754-1760.
45.Carlsson A, W.D., Ingvarsson J, et al., Serum protein profiling of systemic lupus erythematous and systemic sclerosis using recombinant antibody microarrays. Molecular and cellular proteomics 2011; 10(5):M110.005033.
Article citation:
Sam Straw., Stratified medicine approach for systemic sclerosis: state of the art and the need for clinical biomarkers. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35):1754-1762.
Research article
Salah El Din Abdel Hag1 , Sania A. Shaddad2*, Tigani Hassan3, Sumaya I Abass4,
A.K Muddathir5 & Shayoub M. E. A6.
Affiliation:-
1Department of Pharmacology, College of Medicine, University of Bahr Elghazal, Sudan
2Department of Pharmacology, Faculty of Medicine, University of Khartoum, Sudan
3Department of Medicine, Pharmacology & Toxicology, Faculty of Veterinary Medicine University of Khartoum, Sudan
4Microbiology-Veterinary Research Centre, Khartoum Sudan
5Department of Pharmacogonosy, Faculty of Pharmacy, University of Khartoum, Sudan.
6Department of Pharmaceutics, Faculty of Pharmacy, University of Khartoum, Sudan
The name of the Department and Institution to which the work should be attributed:-
Department of Pharmacology,
Department of Medicine,
Microbiology-Veterinary Research Centre,
Department of Pharmacogonosy,University of Khartoum, Sudan.
Department of Pharmacology, College of Medicine, University of Bahr Elghazal, Sudan.
*Corresponding author:
Dr. Sania A. Shaddad.
Department of Pharmacology, Faculty of Medicine, University of Khartoum, Sudan.
Abstract:
Antimicrobial actions of ox bile were tested on pathogenic bacterial isolatess under aseptic conditions using standard methods. These included Staphylococcus albus, Proteus spp., Bacillus Gram +ve spp, Staphylococcus aureus, Klebsiella spp., Pseudomonas aeruginosa, Corynebacterium pseudotuberculosis, Escherichia vulneris, Bacillus subtilis (Chemotherapeutic sensitive), Staphylococcus saprophyticus; Enterobacter spp.; Micrococcus variant; Staphylococcus albus yellow-pigment contaminant; Staphylococcus epidermidis.
Whole ox bile was bacteristatic to all the microorganisms. At the concentration of 33% ox bile was bacteristatic to Coryrebacterium pseudtuberculosis, Micrococcus variant, Staphylococcus albus, and Staphylococcus saprophyticus.
At the concentration of 33% ox bile partially inhibited the growth of Micrococcus luteus, Bacillus subtilis, Enterobacter spp, Staphylococcus epidermidis, Staphylococcus albus, Proteus spp., Bacillus spp., Staphylococcus aureus, Klebsiella spp., Pseudomonas spp, Corynebacterium spp. Escherichia vulneris and Bacillus subtilis were not sensitive to 33% of ox bile.
Key Words: MIC; Ox bile; bactericidal.
REFERENCES
1.Abdel Hag, S. E. A. (2004). A pharmacoligical study of the assumed intoxication by camel liver consumption M.Sc. Thesis, University of Khartoum, Sudan.
2.Bockus, H. L. (1953). Affections of the gallbladder and bile ducts, Gastro-entrologly W. B. Saunders, Philadelphia: vol III. P. 424 – 715.
3. Collee, J. G.; Fraser, A. G., Marmion, B. P. and Simmons, A. (1996). Practical Medical Microbiolgy. 14th ed. Churchill Livingstone Inc. 650 Avenue of the Americas, New York, N.Y. 10011, USA.
4.Elsanousi, S.M.; Ali, B.H. and El Sheikh, A. (2004). The influence of deoxycholic acid on the inhibitory effect of Furazolidone in vitro, (unpublished paper).
5.Garriga, Paseual, Selection of lactobacilli for chicken probiotic adjuncts, Journal of applied microbiology 1997; 84(1):125.
6.Horrall, O. H. (1938). Bile, its toxicity and relation to disease. Chicago, University of Chicago Press. P 31.
7.Hulitanen, C.M.Bile acid inhibition of Clastridium botulinum, Applied Environmental microbiology 1979; 38: 216 –218.
8.Kalashinic, S.A. Bactericidal action of human and bovine bile on Staphylococci, Varachebonoe Delo. 1973; 10, 132 – 154.
9.Rampone, Alfred J. The effect of bile salt and raw bile on the intestinal absorption of micellar fatty acid in the rat in vitro, J. physiol 1972-A;222: 679 – 690.
10.Rampone, Alfred J. Bile salt & non-bile salt components in bile affect cholesterol uptake by rat intestine in vitro, J. physiol 1972-B;227 (3): 889 – 898.
11.Tkachuch, N.I. Protection of antimicrobial activity of Furazolidone by bile acids. Vrachebonoe Delo., 1983; 4: 110 – 112.
Article citation:-
Shaddad A. Sania et al. The in vitro inhibitory effect of ox bile on selected bacteria . Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October;35(35):1767-1773.Available at http://www.jpbms.info
Copyright © 2013 Shaddad A. Sania et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Review article
Nadia Salem & *Azman Abdullah
Affiliation:-
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Campus, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
The name of the Department and Institution to which the work should be attributed:-
Department of Pharmacology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Campus, Jalan Raja Muda Abdul Aziz, 50300 Kuala Lumpur, Malaysia.
Author contributions
Both the author contributed equally to this paper.
*Corresponding author:
Dr. Azman Abdullah,
Department of Pharmacology,
Faculty of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur Campus, Jalan Raja Muda Abdul Aziz,
50300 Kuala Lumpur, Malaysia.
Tel : 006-03-92897508 (Office)
006-016-3185342 (Mobile)
Fax : 006-03-26938205
Abstract:
Carcinogenesis involves multiple steps ranging from the transition of normal to pre-initiated cells to invasive carcinoma. Thus, carcinogenesis provides ample opportunities for chemoprevention. In this context, many naturally-occurring dietary compounds found in fruits and vegetables that are consumed daily have been shown to possess cancer-preventive effects. Sulforaphane (SFN) is a phytochemical compound found in cruciferous vegetables. SFN, a dietary isothiocyanate compound derived from a glucosinolate precursor, has been shown to be a very potent chemopreventive agent in numerous animal carcinogenesis models as well as in cell culture models. SFN exerts its chemopreventive effects by regulating diverse molecular mechanisms. In this review, the molecular mechanisms of SFN which relates to cancer chemoprevention are discussed. These mechanisms include the regulation of phase I and phase II drug metabolizing enzymes. In addition, the influence exerted by sulforaphane upon signaling pathways relating to apoptosis, cell cycle arrest and transcription factors Nrf2, NF-κB and AP-1 are also discussed.
Key Words: Cancer chemoprevention; sulforaphane; phase I drug metabolizing enzymes; phase II drug metabolizing enzymes; apoptosis; cell cycle arrest; histone deacetylase; Nrf2, NF-κB; AP-1, COX-2.
REFERENCES
1.Fahey JW, Zalcmann AT, Talalay P. The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry. 2001;56(1):5-51.
2.van Poppel G, Verhoeven DTH, Verhagen H, Goldbohm RA. Brassica vegetables and cancer prevention epidemiology and mechanisms. Adv Exp Med Biol. 1999;472:159-68.
3.Kushad MM, Brown AF, Kurilich AC, et al. Variation of glucosinolates in vegetable crops of Brassica oleracea. J Agric Food Chem. 1999;47(4):1541-8.
4.Fahey J, Talalay P. Antioxidant functions of sulforaphane: a potent inducer of Phase II detoxication enzymes. Food Chem Toxicol. 1999;37(9):973-9.
5.Shapiro TA, Fahey JW, Wade KL, et al. Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts metabolism and excretion in humans. Cancer Epidemiol Biomarkers Prev. 2001;10(5):501-8.
6.Matusheski NV, Jeffery EH. Comparison of the bioactivity of two glucoraphanin hydrolysis products found in broccoli, sulforaphane and sulforaphane nitrile. J Agric Food Chem. 2001;49(12):5743-9.
7.Wittstock U, Halkier BA. Glucosinolate research in the Arabidopsis era. Trends Plant Sci. 2002;7(6):263-70.
8.Hayes JD, Kelleher MO, Eggleston IM. The cancer chemopreventive actions of phytochemicals derived from glucosinolates. Eur J Nutr. 2008;47:73-88.
9.Berenblum I, Armuth V. Two independent aspects of tumor promotion. Biochim Biophys Acta. 1981;651(1):51.
10.Heidelberger C, Freeman AE, Pienta RJ, et al. Cell transformation by chemical agents--a review and analysis of the literature. A report of the US Environmental Protection Agency Gene-Tox Program. Mutat Res. 1983;114(3):283.
11.Weinberg F, Chandel NS. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci. 2009;66(23):3663-73.
12.Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
13.Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006;71(10):1397-421.
14.Juge N, Mithen R, Traka M. Molecular basis for chemoprevention by sulforaphane: a comprehensive review. Cell Mol Life Sci. 2007;64(9):1105-27.
15.Wattenberg LW. Chemoprevention of cancer. Cancer Res. 1985;45(1):1-8.
16.Elbarbry F, Elrody N. Potential health benefits of sulforaphane: A review of the experimental, clinical and epidemiological evidences and underlying mechanisms. J Med Plant Res. 2011;5:473-84.
17.Hansson LE, Nyrén O, Bergström R, Wolk A, Lindgren A, Baron J, et al. Diet and risk of gastric cancer. A population‐based case‐control study in Sweden. Int J Cancer. 1993;55(2):181-9.
18.Spitz MR, Duphorne CM, Detry MA, Pillow PC, Amos CI, Lei L, et al. Dietary intake of isothiocyanates: evidence of a joint effect with glutathione S-transferase polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9(10):1017-20.
19.Zhao B SA, Lee EJ. Dietary isothiocyanates, glutathione Stransferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev. 2001;10(10):63–7.
20.Canene-Adams K, Lindshield BL, Wang S, et al. Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas. Cancer Res. 2007;67(2):836-43.
21.Kirsh VA, Peters U, Mayne ST, et al. Prospective study of fruit and vegetable intake and risk of prostate cancer. J Natl Cancer Inst. 2007;99(15):1200-9.
22.Lin HJ, Probst-Hensch NM, Louie AD, et al. Glutathione transferase null genotype, broccoli, and lower prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 1998;7(8):647-52.
23.Seow A, Yuan JM, Sun CL, et al. Dietary isothiocyanates, glutathione S-transferase polymorphisms and colorectal cancer risk in the Singapore Chinese Health Study. Carcinogenesis. 2002;23(12):2055-61.
24.Fowke JH, Chung FL, Jin F, et al. Urinary isothiocyanate levels, brassica, and human breast cancer. Cancer Res. 2003;63(14):3980-6.
25.Ambrosone CB, McCann SE, Freudenheim JL, et al. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004;134(5):1134-8.
26.Zhang Y. Role of glutathione in the accumulation of anticarcinogenic isothiocyanates and their glutathione conjugates by murine hepatoma cells. Carcinogenesis. 2000;21(6):1175-82.
27.Zhao H, Lin J, Grossman HB, et al. Dietary isothiocyanates, GSTM1, GSTT1, NAT2 polymorphisms and bladder cancer risk. Int J Cancer. 2007;120(10):2208-13.
28.Cornelis MC, El-Sohemy A, Campos H. GSTT1 genotype modifies the association between cruciferous vegetable intake and the risk of myocardial infarction. Am J Clin Nutr. 2007;86(3):752-8.
29.Wogan GN, Hecht SS, Felton JS, et al. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004;14(6):473-86.
30.Mahéo K, Morel F, Langouët S, et al. Inhibition of cytochromes P-450 and induction of glutathione S-transferases by sulforaphane in primary human and rat hepatocytes. Cancer Res. 1997;57(17):3649-52.
31.Barcelo S, Gardiner JM, Gescher A, Chipman JK. CYP2E1-mediated mechanism of anti-genotoxicity of the broccoli constituent sulforaphane. Carcinogenesis. 1996;17(2):277-82.
32.Pool-Zobel B, Veeriah S, Böhmer FD. Modulation of xenobiotic metabolising enzymes by anticarcinogens—focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutat Res. 2005;591(1):74-92.
33.Saracino MR, Lampe JW. Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention. Nutr Cancer. 2007;59(2):121-41.
34.Vasiliou V, Ross D, Nebert DW. Update of the NAD (P) H: quinone oxidoreductase (NQO) gene family. Human genomics. 2006;2(5):329-35.
35.Dinkova-Kostova AT, Fahey JW, Wade KL, et al. Induction of the phase 2 response in mouse and human skin by sulforaphane-containing broccoli sprout extracts. Cancer Epidemiol Biomarkers Prev. 2007;16(4):847-51.
36.Bacon JR, Williamson G, Garner RC, et al. Sulforaphane and quercetin modulate PhIP–DNA adduct formation in human HepG2 cells and hepatocytes. Carcinogenesis. 2003;24(12):1903-11.
37.Munday R, Munday CM. Induction of phase II detoxification enzymes in rats by plant-derived isothiocyanates: comparison of allyl isothiocyanate with sulforaphane and related compounds. J Agric Food Chem. 2004;52(7):1867-71.
38.Jones SB, Brooks JD. Modest induction of phase 2 enzyme activity in the F-344 rat prostate. BMC cancer. 2006;6(1):62.
39.Prestera T, Talalay P. Electrophile and antioxidant regulation of enzymes that detoxify carcinogens. PNAS. 1995;92(19):8965-9.
40.Jiang ZQ, Chen C, Yang B, et al. Differential responses from seven mammalian cell lines to the treatments of detoxifying enzyme inducers. Life Sci. 2003;72(20):2243-53.
41.Basten GP, Bao Y, Williamson G. Sulforaphane and its glutathione conjugate but not sulforaphane nitrile induce UDP-glucuronosyl transferase (UGT1A1) and glutathione transferase (GSTA1) in cultured cells. Carcinogenesis. 2002;23(8):1399-404.
42.Švehlíková V, Wang S, Jakubíková J, et al. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA1 in CaCo-2 cells. Carcinogenesis. 2004;25(9):1629-37.
43.Brooks JD, Paton VG, Vidanes G. Potent induction of phase 2 enzymes in human prostate cells by sulforaphane. Cancer Epidemiol Biomarkers Prev. 2001;10(9):949-54.
44.Lin W, Wu RT, Wu T, et al. Sulforaphane suppressed LPS-induced inflammation in mouse peritoneal macrophages through Nrf2 dependent pathway. Biochem Pharmacol. 2008;76(8):967-73.
45.Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Mutat Res. 2007;635(2-3):90.
46.Gamet-Payrastre L, Li P, Lumeau S, et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res. 2000;60(5):1426-33.
47.Singh SV, Srivastava SK, Choi S, et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem. 2005;280(20):19911-24.
48.Shen G, Xu C, Chen C, et al. p53-independent G 1 cell cycle arrest of human colon carcinoma cells HT-29 by sulforaphane is associated with induction of p21 CIP1 and inhibition of expression of cyclin D1. Cancer Chemother Pharmacol. 2006;57(3):317-27.
49.Singh SV, Warin R, Xiao D, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res. 2009;69(5):2117-25.
50.Myzak MC, Dashwood RH. Chemoprotection by sulforaphane: keep one eye beyond Keap1. Cancer Lett. 2006;233(2):208-18.
51.Shan Y, Sun C, Zhao X, et al. Effect of sulforaphane on cell growth, G (0)/G (1) phase cell progression and apoptosis in human bladder cancer T24 cells. Int J Oncol. 2006;29(4):883.
52.Telang U, Brazeau DA, Morris ME. Comparison of the effects of phenethyl isothiocyanate and sulforaphane on gene expression in breast cancer and normal mammary epithelial cells. Exp Biol Med. 2009;234(3):287-95.
53.Bryant CS, Kumar S, Chamala S, et al. Sulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cells. Mol Cancer. 2010; 9(1):47.
54.Shankar S, Ganapathy S, Srivastava RK. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis. Clin Cancer Res. 2008;14(21):6855-66.
55.Mi L, Wang X, Govind S, et al. The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non–small lung cancer cells. Cancer Res. 2007; 67(13):6409-16.
56.Mi L, Xiao Z, Hood BL, et al. Covalent Binding to Tubulin by Isothiocyanates. J Biol Chem. 2008;283(32):22136-46.
57.Jiang H, Shang X, Wu H, et al. Combination treatment with resveratrol and sulforaphane induces apoptosis in human U251 glioma cells. Neurochem Res. 2010;35(1):152-61.
58.Chiao J, Chung F, Kancherla R, et al. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Int J Oncol. 2002;20(3):631.
59.Nogales E. Structural insights into microtubule function. Ann Rev Biochem. 2000;69(1):277-302.
60.Myzak MC, Karplus PA, Chung FL, Dashwood RH. A Novel Mechanism of Chemoprotection by Sulforaphane Inhibition of Histone Deacetylase. Cancer Res. 2004;64(16):5767-74.
61.Myzak MC, Hardin K, Wang R, et al. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis. 2006; 27(4):811-9.
62.Myzak MC, Dashwood WM, Orner GA, et al. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apcmin mice. FASEB J. 2006;20(3):506-8.
63.Fimognari C, Nüsse M, Berti F, Iori R, et al. Sulforaphane Modulates Cell Cycle and Apoptosis in Transformed and Non‐transformed Human T Lymphocytes. Ann N Y Acad Sci. 2003;1010(1):393-8.
64.Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 1(3):194-202.
65.Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. Semin Cancer Biol. 2007; 17(5):363-9.
66.Ma X, Fang Y, Beklemisheva A, et al. Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells. Int J Oncol. 2006;28(5):1287-93.
67.Beklemisheva AA, Fang Y, Feng J, et al. Epigenetic mechanism of growth inhibition induced by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer Res. 2006; 26(2A):1225-30.
68.Pledgie-Tracy A, Sobolewski MD, Davidson NE. Sulforaphane induces cell type–specific apoptosis in human breast cancer cell lines. Mol Cancer Ther. 2007; 6(3):1013-21.
69.Wang L, Liu X, Fang Y, et al. De-repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of HDACs and c-Myc. Int J Oncol. 2008;33(2):375-80.
70.Myzak MC, Tong P, Dashwood WM, et al. Sulforaphane retards the growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med. 2007;232(2):227-34.
71.Huang B, Laban M, Leung CHW, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ. 2005;12(4):395-404.
72.Zhu P, Martin E, Mengwasser J, et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell. 2004; 5(5):455-63.
73.Wilson AJ, Byun DS, Popova N, et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem. 2006;281(19):13548-58.
74.Spurling CC, Godman CA, Noonan EJ, et al. HDAC3 overexpression and colon cancer cell proliferation and differentiation. Mol Carcinog. 2007;47(2):137-47.
75.Wilson AJ, Byun DS, Nasser S, et al. HDAC4 promotes growth of colon cancer cells via repression of p21. Mol Biol Cell. 2008;19(10):4062-75.
76.Ashktorab H, Belgrave K, Hosseinkhah F, et al. Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci. 2009;54(10):2109-17.
77.Senese S, Zaragoza K, Minardi S, et al. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007; 27(13):4784-95.
78.Ma H, Nguyen C, Lee KS, Kahn M. Differential roles for the coactivators CBP and p300 on TCF/β-catenin-mediated survivin gene expression. Oncogene. 2005;24(22):3619-31.
79.Heiss E, Herhaus C, Klimo K, et al. Nuclear factor kappa B is a molecular target for sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem 2001; 276:32008–15.
80.Srivastava SK, Singh SV. Cell cycle arrest, apoptosis induction and inhibition of nuclear factor kappa B activation in anti-proliferative activity of benzyl isothiocyanate against human pancreatic cancer cells. Carcinogenesis. 2004;25(9):1701-9.
81.Xu C SG, Chen C, Gélinas C, Kong AN. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene. 2005;24:4486–95.
82.Kallifatidis G, Rausch V, Baumann B, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-ĸB-induced antiapoptotic signalling. Gut. 2009;58:949–63.
83.Estrov Z, Manna SK, Harris D, et al. Phenylarsine oxide blocks interleukin-1b-induced activation of the nuclear transcription factor NF-ĸB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. Blood. 1999; 94:2844-53.
84.Estrov Z Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1b-induced activation of the nuclear transcription factor NF-ĸB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003; 102:987-95.
85.Ben-Neriah Y. Regulatory functions of ubiquitination in the immune system. Nat. Immunol. 2002; 3:20-6.
86.A.C. Bharti ND, S. Singh, B.B. Aggarwal. Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-ĸB and IĸBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood. 2003; 101:1053–62.
87.Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-ĸB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175–84.
88.Shishodia S, Aggarwal BB. Nuclear factor-κB: a friend or a foe in cancer? Biochem Pharmacol. 2004; 68(6):1071-80.
89.Takada Y Singh S, Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF-ĸB activation induced by various inflammatory stimuli and its role in down-regulation of NF-ĸB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 2004; 279:15096–104.
90.Vile GF, Tanew-Ilitschew A, Tyrrell RM. Activation of NF-ĸB in human skin fibroblasts by the oxidative stress generated by UVA radiation. Photochem Photobiol. 1995;62:463–68.
91.Kim SJ Kang SY, Shin HH, Choi HS. Sulforaphane inhibits osteoclastogenesis by inhibiting nuclear factor-ĸB. Mol Cells 2005; 20:364–70
92.Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236(2):313-22.
93.Alam J, Wicks C, Stewart D, et al. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells role of p38 kinase and Nrf2 transcription factor. J Biol Chem. 2000; 275(36):27694-702.
94.Jeong W, Keum Y, Chen C, et al. Differential expression and stability of endogenous nuclear factor E2-related factor 2 (Nrf2) by natural chemopreventive compounds in HepG2 human hepatoma cells. J Biochem Mol Biol. 2005; 38(2):167.
95.He X, Lin GX, Chen MG, et al. Protection against Chromium (VI)–Induced Oxidative Stress and Apoptosis by Nrf2. Recruiting Nrf2 into the Nucleus and Disrupting the Nuclear Nrf2/Keap1 Association. Toxicol Sci. 2007;98(1):298-309.
96.Hong F, Freeman ML, Liebler DC. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol. 2005; 18(12):1917-26.
97.Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem. 2010; 17(20):2141.
98.Li Y, Kong D, Wang Z, Sarkar FH. Regulation of microRNAs by natural agents: an emerging field in chemoprevention and chemotherapy research. Pharm Res. 2010a; 27(6):1027-41.
99.Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-68.
100.Zhu M, Zhang Y, Cooper S, et al. Phase II enzyme inducer, sulforaphane, inhibits UVB‐induced AP‐1 activation in human keratinocytes by a novel mechanism. Mol Carcinog. 2004; 41(3):179-86.
101.Jeong WS, Kim IW, Hu R, Kong ANT. Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm Res. 2004; 21(4):649-60.
102.Kyung JW TK. Sulforaphane suppresses lipo-polysaccharide-induced cyclooxygenase-2 (COX-2) expression through the modulation of multiple targets in COX-2 gene promoter. . Int Immunopharmacol. 2007; 7:1776–83.
103.Thejass P, Kuttan G. Immunomodulatory activity of Sulforaphane, a naturally occurring isothiocyanate from broccoli (Brassica oleracea). Phytomedicine. 2007; 14(7):538-45.
104.Sharma C, Sadrieh L, Priyani A, et al. Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells. Cancer Epidemiol. 2011; 35(3):272-8.
Article citation:-
Salem Nadia & Abdullah Azman. Sulforaphane and its function in cancer chemoprevention. Journal of pharmaceutical and biomedical sciences (J Pharm Biomed Sci.) 2013 October; 35(35):1788-1795.Available at http://www.jpbms.info
Copyright © 2013 Salem Nadia & Abdullah Azman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.